Treating to goal: Challenges of current management

European Journal of Endocrinology, Supplement

Volumn 151, Issue 2, 2004, Pages

  Barnett, A H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES CONTROL; DIABETES CONTROL AND COMPLICATIONS TRIAL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE COURSE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT ATTITUDE; PATIENT EDUCATION; POLYPHARMACY; PSYCHOLOGICAL ASPECT; RISK REDUCTION; SELF CARE; TREATMENT OUTCOME; UK PROSPECTIVE DIABETES STUDY;

DIABETES MELLITUS, TYPE 2; GOALS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 8644223948     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993 329 977-986.
2. Reichard P, Nilsson BY & Rosenqvist V. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 1993 329 304-309.
3. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853.
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N & Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice 1995 28 103-117.
5. American Diabetes Association. Clinical Practice Recommendations 2000. Diabetes Care 2000 23 (Suppl 1) S1-S116.
6. European Diabetes Policy Group. A desktop guide to Type 1 (insulin-dependent) diabetes mellitus. Diabetic Medicine 1999 16 253-266.
7. American College of Endocrinology. Consensus Status on Guidelines for Glycemic Control. Endocrine Practice 2002 8 (Suppl 1) 5-11.
8. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabetic Medicine 1999 16 716-730.
9. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, Davis R, Field R, Frost G, Marshall S, Roddick J, Tesfaye S, Withers H, Suckling R, Smith S, Griffin S, Kaltenthaler E, Peters J & Feder G. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR. University of Sheffield, 2001.
10. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 diabetes. Practical Targets and Treatments, edn 3. Sydney: Health Communications Australia Pty Ltd and In vivo. 2002.
11. UKPDS Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999 22 1125-1136.
12. Clarke P, Gray A, Legood R, Briggs A & Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003 20 442-450.
13. Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R & Turner R. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. British Medical Journal 2000 320 1373-1378.
14. Herman WH & Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998 21 (Suppl 3) C19-C24.
15. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinology and Metabolism Clinics of North America 1996 25 243-254.
16. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995 44 968-983.
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC & Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 2000 321 405-412.
18. Harris MI, Eastman RC, Cowie CC, Flegal KM & Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999 22 403-408.
19. Chuang LM, Tsai ST, Huang BY & Tai TY. Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia - a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabetic Medicine 2002 19 978-985.
20. Liebl A, Mata M & Eschwege E. CODE-2 Advisory Board. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002 45 S23-S28.
21. O'Hare JP, Raymond NT, Mughal S, Dodd L, Hanif W, Ahmed Y, Mishra K, Jones A, Kumar S, Szczepura A, Hillhouse EW & Barnett AH, on behalf of the UKADS study group. Evaluation of delivery of enhanced diabetes care for patients of South Asian ethnicity: the United Kingdom Asian Diabetes Study (UKADS). Diabetic Medicine (In Press).
22. Donnan PT, MacDonald TM & Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabetic Medicine 2002 19 279-284.
23. Morris AD, Brennan GM, MacDonald TM & Donnan PT. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000 49 (Suppl 1) 307.
24. Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B & Christiansen JS. Issues relating to the early or earlier use of insulin in type 2 diabetes. Practical Diabetes International 2003 20 63-71.
25. Snoek FJ. Barriers to good glycaemic control: the patient's perspective. International Journal of Obesity and Related Metabolic Disorders 2000 24 (Suppl 3) S12-S20.
26. Diabetes Attitudes. Wishes and Needs (DAWN) Study group. DAWN Study Report, 2001.
27. Gagliardino JJ. Resourcing issues. European Journal of Endocrinology 2004 151 (Suppl) S15-S17.
28. Skinner TC. Psychological barriers. European Journal of Endocrinology 2004 151 (Suppl) S9-S13.
29. Funnell MM. Overcoming obstacles: collaboration for change. European Journal of Endocrinology 2004 151 (Suppl) S19-S22.
30. Heinemann L. Overcoming obstacles: new management options. European Journal of Endocrinology 2004 151 (Suppl) S3-S7.
31. Zgibor JC, Songer TJ, Kelsey SF, Drash AL & Orchard TJ. Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2002 25 1584-1590.
32. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001 24 454-459.
33. Zgibor JC & Simmons D. Barriers to blood glucose monitoring in a multiethnic community. Diabetes Care 2002 25 1772-1777.